Epigral Gears Up for Q3 Reveal on 30th January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Epigral’s Q3 results FY26 are scheduled to be announced on 30th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Epigral Q3 Results 2026 Preview

• Epigral’s revenue is expected to be in the range of ₹645.24 crore, a 3.06% YoY decrease. 
• Profit After Tax, or PAT, is projected to rise by 27.47% YoY. 
• Epigral’s EBITDA is expected to rise to ₹149.60 crore. 
• Net profit is ₹103.63 crore, a rise of 27.47% YoY 

Epigral Share Performance 

• Over the past six months, Epigral’s share price has fallen by 8.95% to ₹538.65.
• Moreover, over the past year, the stock has increased by 12.87%.
• Despite this weak short-term performance, Epigral’s stock has delivered a financially sound 239.85% return over the past 5 years.
• As of 29th January 2026, the stock traded at ₹538.05 per share.

Key Factors to Watch for Epigral Q3 Results FY26 

• Revenue & Volume Growth: Look at topline growth and sales volume trends, especially contribution from high-value derivatives and specialty chemicals.
• Profitability & Margins: Monitor EBITDA and PAT performance along with margin expansion or contraction versus prior quarters.
• Segment Contribution Mix: Check how much revenue is coming from derivatives & speciality products versus basic chemicals, as a higher speciality share can support better margins.
• Capacity Utilisation & New Project Impact: Assess utilisation of existing plants and any early signals from upcoming projects, such as chlorotoluenes or other value chains expected to be commissioned.
• Cost & Realization Trends: Watch raw material costs, product price realizations and their impact on operating efficiency given commodity cycle volatility.

Final Thoughts

Epigral will announce its Q3 FY26 results on 30th January 2026. Analysts expect 3.06% YoY revenue growth, a 27.47% rise in PAT, and a 2.34% fall in EBITDA. Epigral focuses on manufacturing and supplying a diversified range of chlor-alkali, derivatives and specialty chemicals — including caustic soda, epichlorohydrin, CPVC resin & compounds, chloromethanes, hydrogen peroxide and integrated chemical value-chain products — with a strategic shift toward high-value specialty segments and sustainable, backward-integrated chemical production.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here